Skip to Content
Global News Select

Novartis to Buy MorphoSys for $2.9 Billion; Deal Seen Closing in 1st Half

By Denny Jacob

 

Novartis entered into an agreement to acquire biopharmaceutical company MorphoSys for 2.7 billion euros ($2.9 billion).

Swiss drug giant Novartis said that under the agreed transaction, approved by the boards of both companies, it would make a voluntary public takeover for all no-par value bearer shares of MorphoSys for 68 euros a share. The deal is expected to close in the first half of 2024.

Novartis would own pelabresib, a potential treatment for patients with myelofibrosis, among other treatments under the close of the deal. The company said the acquisition expands and complements its pipeline in oncology.

News of Novartis's acquisition comes in the weeks since The Wall Street Journal reported that the company had backed away from its pursuit of heart-drug developer Cytokinetics.

 

Write to Denny Jacob at denny.jacob@wsj.com

 

(END) Dow Jones Newswires

February 05, 2024 17:35 ET (22:35 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Market Updates

Sponsor Center